​

Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IRWD Stock Forecast

Ironwood Pharmaceuticals (IRWD) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $4.80, with a high of $5.70 and a low of $3.70. This represents a 42.43% increase from the last price of $3.37.

$3 $4 $5 $6 $7 $8 $9 $10 $11 $12 High: $5.7 Avg: $4.8 Low: $3.7 Last Closed Price: $3.37

IRWD Stock Rating

Ironwood Pharmaceuticals stock's rating consensus is Hold, based on 30 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (36.67%), 16 Hold (53.33%), 3 Sell (10.00%), and 0 Strong Sell (0.00%).

Hold
Total 30 3 16 11 0 Strong Sell Sell Hold Buy Strong Buy

IRWD Price Target Upside V Benchmarks

TypeNameUpside
StockIronwood Pharmaceuticals42.43%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.04%

Price Target Trends

1M3M12M
# Anlaysts135
Avg Price Target$3.70$4.80$3.84
Last Closing Price$3.37$3.37$3.37
Upside/Downside9.79%42.43%13.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26112--4
Feb, 26112--4
Jan, 26--4--4
Dec, 25--4--4
Nov, 25--5--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Amy LiJefferies$3.70$3.602.78%9.79%
Jan 05, 2026Craig-Hallum$5.70$4.2733.49%69.14%
Jan 04, 2026Wells Fargo$5.00$4.2717.10%48.37%
Nov 26, 2025Craig-Hallum$3.80$3.83-0.78%12.76%
Apr 14, 2025Faisal KhurshidLeerink Partners$1.00$0.6553.85%-70.33%
Jan 31, 2025Mohit BansalWells Fargo$7.00$2.34199.15%107.72%
Sep 09, 2024Faisal KhurshidLeerink Partners$5.00$4.5110.86%48.37%
Aug 09, 2024Mohit BansalWells Fargo$12.00$4.05196.30%256.08%
May 22, 2024David AmsellemPiper Sandler$18.00$6.82163.93%434.12%
May 22, 2024Mohit BansalWells Fargo$14.00$6.78106.49%315.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026JefferiesHoldHoldhold
Jan 05, 2026Craig-HallumHoldBuyupgrade
Jan 05, 2026CitigroupMarket PerformOutperformupgrade
Jan 04, 2026Wells FargoPositivePositivehold
Nov 26, 2025Craig-HallumHoldHoldhold
Apr 16, 2025Craig-HallumHolddowngrade
Apr 15, 2025JefferiesHolddowngrade
Apr 14, 2025CitigroupMarket Performdowngrade
Jan 31, 2025Wells FargoOverweightOverweighthold
Oct 01, 2024JMP SecuritiesMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.26$1.13$-6.45$0.01$0.72---
Avg Forecast$3.26$0.97$-5.85$0.10$0.23$0.81$0.70$1.12
High Forecast$3.64$1.06$-5.45$0.11$0.43$1.02$0.80$1.28
Low Forecast$2.87$0.88$-6.24$0.09$0.14$0.60$0.61$0.98
Surprise %-16.49%10.26%-90.00%213.04%---

Revenue Forecast

$250M $340M $430M $520M $610M $700M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$413.75M$410.60M$442.74M$351.41M$296.15M---
Avg Forecast$407.40M$411.69M$442.86M$353.31M$338.35M$416.18M$586.60M$540.00M
High Forecast$444.86M$440.55M$448.65M$355.44M$379.22M$463.03M$652.64M$600.80M
Low Forecast$370.55M$381.04M$438.73M$350.93M$309.86M$375.20M$528.84M$486.83M
Surprise %1.56%-0.27%-0.03%-0.54%-12.47%---

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$528.45M$175.06M$-1.00B$880.00K$116.03M---
Avg Forecast$357.75M$203.32M$-1.00B$15.69M$32.76M$125.57M$109.80M$174.09M
High Forecast$429.30M$243.98M$-801.79M$17.82M$66.55M$158.13M$124.73M$199.57M
Low Forecast$286.20M$162.65M$-1.20B$13.55M$22.19M$93.02M$94.88M$151.80M
Surprise %47.71%-13.90%--94.39%254.19%---

IRWD Forecast FAQ

Is Ironwood Pharmaceuticals stock a buy?

Ironwood Pharmaceuticals stock has a consensus rating of Hold, based on 30 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 16 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Ironwood Pharmaceuticals is a neutral investment for most analysts.

What is Ironwood Pharmaceuticals's price target?

Ironwood Pharmaceuticals's price target, set by 30 Wall Street analysts, averages $4.8 over the next 12 months. The price target range spans from $3.7 at the low end to $5.7 at the high end, suggesting a potential 42.43% change from the previous closing price of $3.37.

How does Ironwood Pharmaceuticals stock forecast compare to its benchmarks?

Ironwood Pharmaceuticals's stock forecast shows a 42.43% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (26.04%).

What is the breakdown of analyst ratings for Ironwood Pharmaceuticals over the past three months?

  • March 2026: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 25.00% Strong Buy, 25.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Ironwood Pharmaceuticals’s EPS forecast?

Ironwood Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0.81, marking a 12.50% increase from the reported $0.72 in 2025. Estimates for the following years are $0.7 in 2027, and $1.12 in 2028.

What is Ironwood Pharmaceuticals’s revenue forecast?

Ironwood Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $416.18M, reflecting a 40.53% increase from the reported $296.15M in 2025. The forecast for 2027 is $586.6M, and $540M for 2028.

What is Ironwood Pharmaceuticals’s net income forecast?

Ironwood Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $125.57M, representing an 8.22% increase from the reported $116.03M in 2025. Projections indicate $109.8M in 2027, and $174.09M in 2028.